View in EDS

A plain language summary of POLARIS: a study to look at different doses of encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasis.

Saved in:
Bibliographic Details
Title: A plain language summary of POLARIS: a study to look at different doses of encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasis.
Authors: Menzies AM; aMelanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, Australia., Long GV; aMelanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, Australia., Kohn A; bOregon Health Sciences University, Division of Hematology/Medical Oncology, School of Medicine, Portland, OR, USA., Tawbi H; cUniversity of Texas MD Anderson Cancer Center, Department of Melanoma Medical Oncology Houston, TX, USA., Webe J; dLaura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA., Flaherty K; eMassachusetts General Hospital, Massachusetts General Cancer Center, Boston, MA, USA., McArthur GA; fPeter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology University of Melbourne, Melbourne, VIC, Australia., Ascierto PA; gAzienda Universitaria Policlinico Federico II, Unit of Melanoma Cancer Immunotherapy and Innovative therapy, Naples, Italy., Pfluger Y; hAlexander Fleming Institute, Buenos Aires, Argentina., Lewis K; iUniversity of Colorado, Health Center, Medical Oncology, Denver, CO, USA., Tsai KK; jUniversity of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA., Hamid O; kThe Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, USA., Prenen H; lUniversity Hospital Antwerp, Oncology Department, Antwerp, Belgium., Fein L; hAlexander Fleming Institute, Buenos Aires, Argentina., Wang E; mPfizer, New York, NY, USA., Guenzel C; mPfizer, New York, NY, USA., Zhang F; mPfizer, New York, NY, USA., Kleh JF; aMelanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, Australia.; mPfizer, New York, NY, USA., di Pietro A; nPfizer Srl, Milan, Italy., Davies MA; cUniversity of Texas MD Anderson Cancer Center, Department of Melanoma Medical Oncology Houston, TX, USA.
Source: Future oncology (London, England) [Future Oncol] 2025 Jun; Vol. 21 (14), pp. 1703-1711. Date of Electronic Publication: 2025 May 26.
Publication Type: Journal Article
Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40418081
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A plain language summary of POLARIS: a study to look at different doses of encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasis.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Menzies+AM%22">Menzies AM</searchLink>; aMelanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, Australia.<br /><searchLink fieldCode="AU" term="%22Long+GV%22">Long GV</searchLink>; aMelanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, Australia.<br /><searchLink fieldCode="AU" term="%22Kohn+A%22">Kohn A</searchLink>; bOregon Health Sciences University, Division of Hematology/Medical Oncology, School of Medicine, Portland, OR, USA.<br /><searchLink fieldCode="AU" term="%22Tawbi+H%22">Tawbi H</searchLink>; cUniversity of Texas MD Anderson Cancer Center, Department of Melanoma Medical Oncology Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Webe+J%22">Webe J</searchLink>; dLaura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Flaherty+K%22">Flaherty K</searchLink>; eMassachusetts General Hospital, Massachusetts General Cancer Center, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22McArthur+GA%22">McArthur GA</searchLink>; fPeter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology University of Melbourne, Melbourne, VIC, Australia.<br /><searchLink fieldCode="AU" term="%22Ascierto+PA%22">Ascierto PA</searchLink>; gAzienda Universitaria Policlinico Federico II, Unit of Melanoma Cancer Immunotherapy and Innovative therapy, Naples, Italy.<br /><searchLink fieldCode="AU" term="%22Pfluger+Y%22">Pfluger Y</searchLink>; hAlexander Fleming Institute, Buenos Aires, Argentina.<br /><searchLink fieldCode="AU" term="%22Lewis+K%22">Lewis K</searchLink>; iUniversity of Colorado, Health Center, Medical Oncology, Denver, CO, USA.<br /><searchLink fieldCode="AU" term="%22Tsai+KK%22">Tsai KK</searchLink>; jUniversity of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Hamid+O%22">Hamid O</searchLink>; kThe Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Prenen+H%22">Prenen H</searchLink>; lUniversity Hospital Antwerp, Oncology Department, Antwerp, Belgium.<br /><searchLink fieldCode="AU" term="%22Fein+L%22">Fein L</searchLink>; hAlexander Fleming Institute, Buenos Aires, Argentina.<br /><searchLink fieldCode="AU" term="%22Wang+E%22">Wang E</searchLink>; mPfizer, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Guenzel+C%22">Guenzel C</searchLink>; mPfizer, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Zhang+F%22">Zhang F</searchLink>; mPfizer, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Kleh+JF%22">Kleh JF</searchLink>; aMelanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, Australia.; mPfizer, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22di+Pietro+A%22">di Pietro A</searchLink>; nPfizer Srl, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Davies+MA%22">Davies MA</searchLink>; cUniversity of Texas MD Anderson Cancer Center, Department of Melanoma Medical Oncology Houston, TX, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101256629%22">Future oncology (London, England)</searchLink> [Future Oncol] 2025 Jun; Vol. 21 (14), pp. 1703-1711. <i>Date of Electronic Publication: </i>2025 May 26.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101256629 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1744-8301 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214796694%22">14796694 </searchLink><i>NLM ISO Abbreviation: </i>Future Oncol <i>Subsets: </i>MEDLINE; In Process
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40418081
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/14796694.2025.2495540
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1703
    Titles:
      – TitleFull: A plain language summary of POLARIS: a study to look at different doses of encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasis.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Menzies AM
      – PersonEntity:
          Name:
            NameFull: Long GV
      – PersonEntity:
          Name:
            NameFull: Kohn A
      – PersonEntity:
          Name:
            NameFull: Tawbi H
      – PersonEntity:
          Name:
            NameFull: Webe J
      – PersonEntity:
          Name:
            NameFull: Flaherty K
      – PersonEntity:
          Name:
            NameFull: McArthur GA
      – PersonEntity:
          Name:
            NameFull: Ascierto PA
      – PersonEntity:
          Name:
            NameFull: Pfluger Y
      – PersonEntity:
          Name:
            NameFull: Lewis K
      – PersonEntity:
          Name:
            NameFull: Tsai KK
      – PersonEntity:
          Name:
            NameFull: Hamid O
      – PersonEntity:
          Name:
            NameFull: Prenen H
      – PersonEntity:
          Name:
            NameFull: Fein L
      – PersonEntity:
          Name:
            NameFull: Wang E
      – PersonEntity:
          Name:
            NameFull: Guenzel C
      – PersonEntity:
          Name:
            NameFull: Zhang F
      – PersonEntity:
          Name:
            NameFull: Kleh JF
      – PersonEntity:
          Name:
            NameFull: di Pietro A
      – PersonEntity:
          Name:
            NameFull: Davies MA
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: 2025 Jun
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1744-8301
          Numbering:
            – Type: volume
              Value: 21
            – Type: issue
              Value: 14
          Titles:
            – TitleFull: Future oncology (London, England)
              Type: main
ResultId 1